- |||||||||| oleclumab (MEDI9447) / AstraZeneca, ATG-037 / Antengene
Targeting CD73-adenosine axis for the treatment of multiple myeloma (Section 17; Poster Board #27) - Mar 14, 2023 - Abstract #AACR2023AACR_2555;
The murine myeloma cells were implanted subcutaneously into BALB/c mice, and ATG-037 (100 mg/kg) or vehicle was orally administered BID starting day one post-implantation. ATG-037 demonstrated complete inhibition of CD73 activity without
- |||||||||| ATG-037 / Antengene
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: KEYNOTE-E73: A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 27, 2023
P1, N=98, Recruiting,
ATG-037 demonstrated complete inhibition of CD73 activity without N=36 --> 98 | Trial completion date: Aug 2024 --> Feb 2028 | Trial primary completion date: Mar 2024 --> Aug 2027
- |||||||||| ATG-037 / Antengene
Enrollment open, Trial initiation date, Combination therapy, Monotherapy, Metastases: KEYNOTE-E73: A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 3, 2022
P1, N=36, Recruiting,
N=36 --> 98 | Trial completion date: Aug 2024 --> Feb 2028 | Trial primary completion date: Mar 2024 --> Aug 2027 Not yet recruiting --> Recruiting | Initiation date: Feb 2022 --> Dec 2022
- |||||||||| ATG-037 / Antengene
New P1 trial, Combination therapy, Monotherapy, Checkpoint inhibition, Metastases: KEYNOTE-E73: A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 23, 2022
P1, N=36, Not yet recruiting,
|
